AB Science
Records under this name other than the patents AB Science holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 15 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,472,164 | Masitinib for the Treatment of Sickle Cell Disease Formerly held In force · High confidence | In force | High confidence | |
| US 9,168,245 | Selective protein kinase inhibitors Lapsed on the fee record Ended Oct 27, 2023 · From the USPTO record | Lapsed on the fee record | Ended Oct 27, 2023 | From the USPTO record |
| US 7,423,055 | 2-(3-Aminoaryl)AMINO-4-ARYL-THIAZOLES for the Treatment of Diseases Term ended Ended no later than Aug 1, 2023 · Medium confidence | Term ended | Ended no later than Aug 1, 2023 | Medium confidence |
| US 8,835,435 | 2-(3-Aminoaryl) AMINO-4-ARYL-THIAZOLES and Their Use as C-Kit Inhibitors Term ended Term ended Jul 31, 2023 · High confidence | Term ended | Term ended Jul 31, 2023 | High confidence |
| US 8,993,573 | 2-(3-Aminoaryl) AMINO-4-ARYL-THIAZOLES and Their Use as C-Kit Inhibitiors Term ended Term ended Jul 31, 2023 · Medium confidence | Term ended | Term ended Jul 31, 2023 | Medium confidence |
| US 7,700,610 | Use of tyrosine kinase inhibitors for treating allergic diseases Term ended Term ended Mar 7, 2023 · From the USPTO record | Term ended | Term ended Mar 7, 2023 | From the USPTO record |
| US 7,741,335 | Use of tyrosine kinase inhibitors for treating inflammatory diseases Term ended Term ended Dec 28, 2022 · From the USPTO record | Term ended | Term ended Dec 28, 2022 | From the USPTO record |
| US 7,718,676 | 2-Aminoaryloxazole Compounds as Tyrosine Kinase Inhibitors Lapsed on the fee record Ended May 18, 2022 · High confidence | Lapsed on the fee record | Ended May 18, 2022 | High confidence |
| US 7,678,805 | Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD) Lapsed on the fee record Ended Mar 16, 2022 · From the USPTO record | Lapsed on the fee record | Ended Mar 16, 2022 | From the USPTO record |
| US 8,658,659 | Substituted oxazole derivatives and their use as tyrosine kinase inhibitors Lapsed on the fee record Ended Feb 25, 2022 · From the USPTO record | Lapsed on the fee record | Ended Feb 25, 2022 | From the USPTO record |